Evidence map›Paper›PMID 32777456›Full record

Trial reportJournal of pain and symptom management2021

The Effect of Disclosing Life Expectancy Information on Patients' Prognostic Understanding: Secondary Outcomes From a Multicenter Randomized Trial of a Palliative Chemotherapy Educational Intervention.

Andrea C Enzinger, Hajime Uno, Nadine McCleary, Elizabeth Frank, Hanna Sanoff, Katherine Van Loon, Khalid Matin, Andrea Bullock, Christine Cronin, Janet Bagley and 1 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of pain and symptom management, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Informed consent for genetic testing in hematology.Hematology. American Society of Hematology. Education Program · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea C EnzingerDivision of Population Sciences, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA; Division of Gastrointestinal Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA. Electronic address: andrea_enzinger@dfci.harvard.edu.
Hajime UnoDivision of Population Sciences, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Nadine McClearyDivision of Gastrointestinal Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Elizabeth FrankSusan F. Smith Center for Women's Cancers, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Hanna SanoffDivision of Medical Oncology, University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, USA.
Katherine Van LoonDivision of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Khalid MatinDivision of Medical Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.
Andrea BullockDivision of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Christine CroninDivision of Population Sciences, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Janet BagleyDepartment of Nursing, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.
Deborah SchragDivision of Population Sciences, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA; Division of Gastrointestinal Oncology, Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.

Funding

Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
Video Informed Consent Tools to Improve Care for Patients With Advanced Pancreatic CancerK07CA204201 · NCI · DANA-FARBER CANCER INST · PI ENZINGER, ANDREA C · 2016 to 2020
$878k
NCI NIH HHS K07 CA204201NCI NIH HHS UG1 CA189823NCI NIH HHS UG1 CA233180
6 · The paper itself

Abstract

contextMany advanced patients with cancer have unrealistic prognostic expectations.

objectivesWe tested whether offering life expectancy (LE) statistics within palliative chemotherapy (PC) education promotes realistic expectations.

methodsIn this multicenter trial, patients with advanced colorectal and pancreatic cancers initiating first or second line PC were randomized to usual care versus a PC educational tool with optional LE information. Surveys at two weeks and three months assessed patients' review of the LE module and their reactions; at three months, patients estimated their LE and reported occurrence of prognosis and end-of-life (EOL) discussions. Wilcoxon tests and proportional odds models evaluated between-arm differences in LE self-estimates, and how realistic those estimates were (based on cancer type and line of treatment).

resultsFrom 2015 to 2017, 92 patients were randomized to the intervention and 94 to usual care. At baseline most patients (80.9%) wanted "a lot" or "as much information as possible" about the impact of chemotherapy on LE. Among patients randomized to the intervention, 52.0% reviewed the LE module by two weeks and 66.7% by three months-of whom 88.2% reported the information was important, 31.4% reported it was upsetting, and 3.9% regretted reviewing it. Overall, patients' LE self-estimates were very optimistic; 71.4% of patients with colorectal cancer estimated greater than five years; 50% pancreatic patients estimated greater than two years. The intervention had no effect on the length or realism of patients' LE self-estimates, or on the occurrence of prognostic or EOL discussions.

conclusionsOffering LE information within a PC educational intervention had no effect on patients' prognostic expectations.

Indexed as

Life ExpectancyNeoplasmsDeathHumansPalliative CarePrognosisSurveys and Questionnairesadvanced cancerinformed consentpalliative chemotherapyprognostic communicationprognostic understanding

Identifiers

PMID32777456
PMCPMC7769864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.